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ABSTRACT
Patients with metastatic melanoma bearing V600 mutations in BRAF oncogene 
clinically benefit from the treatment with BRAF inhibitors alone or in combination with 
MEK inhibitors. However, a limitation to such treatment is the occurrence of resistance. 
Tackling the adaptive changes helping cells survive from drug treatment may offer new 
therapeutic opportunities. Very recently the ErbB3 receptor has been shown to act as 
a central node promoting survival of BRAF mutated melanoma. In this paper we first 
demonstrate that ErbB3/AKT hyperphosphorylation occurs in BRAF mutated melanoma 
cell lines following exposure to BRAF and/or MEK inhibitors. This strongly correlates with 
increased transcriptional activation of its ligand neuregulin. Anti-ErbB3 antibodies impair 
the establishment of de novo cell resistance to BRAF inhibition in vitro. In order to more 
potently ablate ErbB3 activity we used a combination of two anti-ErbB3 antibodies directed 
against distinct epitopes of its extracellular domain. These two antibodies in combo with 
BRAF/MEK inhibitors potently inhibit in vitro cell growth and tumor regrowth after drug 
withdrawal in an in vivo xenograft model. Importantly, residual tumor masses from 
mice treated by the antibodies and BRAF/ERK inhibitors combo are characterized almost 
exclusively by large necrotic areas with limited residual areas of tumor growth. Taken 
together, our findings support the concept that triple therapy directed against BRAF/MEK/
ErbB3 may be able to provide durable control of BRAF mutated metastatic melanoma.
INTRODUCTION
Malignant melanoma is the most aggressive form 
of skin cancer. Its incidence has dramatically increased 
wordwide over the past decades, thus becoming a major 
medical problem [1]. Although historical survival rates for 
patients with metastatic melanoma have been low until 
recently [2, 3], clinical management of this disease has 
significantly improved over the last 3–4 years thanks to 
the introduction of two classes of drugs: a) immunological 
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checkpoint inhibitors such as monoclonal antibodies 
against CTLA-4 and PD-1/PD-L1 [4]; b) small molecule 
kinase inhibitors of the RAS/RAF/MAPK pathway for 
the approximately 50% of patients bearing mutations 
of the BRAF oncogene [5]. BRAF mutations usually 
affect the Valine 600 codon changing this aminoacid into 
glutamic acid (V600E) in the majority of cases, but also, 
less frequently, into other aminoacids (V600D, V600R) 
[6]. These mutations cause the constitutive activation of the 
BRAF kinase, which aberrantly induces MAPK/ERK kinases 
[6]. Disease prognosis for melanoma patients bearing BRAF 
V600 mutations has drastically improved in relation to the 
introduction of BRAF inhibitors (BRAFi) two of which, 
vemurafenib and dabrafenib, have already been approved 
by FDA [7, 8]. BRAF inhibitors are active only in tumors 
where V600 BRAF mutations result in constitutively active 
monomers, whereas the same inhibitors induce paradoxical 
tumor promoting effects in RAS mutated melanomas 
because of their ability to promote allosteric activation 
through homo- or hetero-dimerization of wild type B RAF 
isoforms [9, 10]. Although BRAFi induce unprecedented 
objective responses in approximately 45 to 50% of treated 
patients, virtually all responders undergo disease progression 
within 5 to 6 months after initiation of treatment as a 
consequence of the development of de novo drug resistance 
[11, 12]. The mechanisms at the basis of acquired resistance 
have been at the center of intensive investigations. These 
have led to discover in the majority of cases a plethora of 
mutations which cause reactivation of the RAS/RAF/MAPK 
pathway, including NRAS or KRAS mutations, mutant 
BRAF amplifications, alternative BRAF splicing, MAP2K1 
activating mutations and CDKN2A losses [13–16].
The evidence that resistance to BRAFi is caused 
by reactivation of the MAPK pathway has led to the 
development of novel strategies directed to simultaneously 
inhibit BRAF and the downstream MEK kinase in the 
attempt to reduce the emergence of resistance. Indeed, MEK 
inhibitors increase objective response rates, progression free 
survival and, more recently, overall survival when delivered 
in combination with a BRAF inhibitor as compared to 
BRAF inhibitor monotherapy [17–20]. Thus combination 
therapy is expected to become soon the standard of care for 
this subset of patients. However also this approach is unable 
to completely eradicate disease and disease progression 
occurs after an average of approximately 10 months [21]. 
Alternative mechanisms of resistance are related to the 
activation of signaling pathways redundant to MAPK, 
for example overexpression of RTKs, such as PDGFR or 
IGF1R, which promote activation of the PI3K-AKT axis 
[22–24]. These mechanisms have been observed both 
in melanoma cell cultures exposed in vitro to continuous 
selection with BRAF inhibitors, and in post-relapse human 
melanoma tumor samples [14].
An alternative approach to the study of drug 
resistance is the analysis of early adaptive changes taking 
place in cells shortly after drug exposure. We believe that 
a better knowledge of these early events may help develop 
new strategies aiming at circumventing the establishment 
of drug resistance. Using this approach our laboratory as 
well as others have recently shown that the ErbB3 receptor 
is involved in the activation of an early feedback survival 
loop soon after drug exposure which leads to increased 
phosphorylation of the prosurvival AKT kinase [25–27]. A 
distinguishing feature of our observations was that, upon 
exposure to BRAF or MEK inhibitors, ErbB3 does not 
undergo transcriptional activation but instead a selective 
increase of its phosphorylation consequent to enhanced 
autocrine production of its ligand neuregulin-1 (NRG1) 
[27]. Also, we were the first to show that activation of the 
ErbB3/AKT axis can be inhibited by co-treatment with 
anti-ErbB3 mAbs [27] and that these antibodies synergize 
with BRAF and MEK inhibitors in short term in vitro 
clonogenic assays [27]. We had previosuly generated 
a group of monoclonal antibodies directed against the 
extracellular domain of human ErbB3 [28] and shown 
that two of these antibodies, named A3 and A4, were 
able to inhibit receptor phosphorylation and melanoma 
cell growth mainly through the induction of receptor 
internalization and degradation [29, 30].
In the present work we have addressed two important 
questions. In first instance we have decided to assess 
whether the ErbB3 autocrine survival loop induced by 
treatment with BRAF and/or MEK inhibitors is a general 
phenomenon using a larger panel of melanoma cell lines 
and whether in vitro treatment with anti-ErbB3 antibodies 
is capable of suppressing the establishment of resistance to 
BRAFi. The second question we have addressed is whether 
a combinatorial approach with two different antibodies 
directed against distinct ErbB3 surface epitopes can better 
inhibit receptor function in BRAF mutated melanomas. 
Previous studies focusing on two other receptors of the 
same family, namely EGFR and ErbB2, have shown that 
a stronger inhibition of their protumorigenic signaling 
activity was achieved with a combination of two antibodies 
against different surface epitopes. This approach was more 
powerful due to a pronounced ability to induce receptor 
downmodulation and redirection into the lysosomal 
degradative pathway [31]. Indeed here we show both 
in vitro and in an in vivo xenograft model that combined 
treatment with A3 and A4 antibodies is able to more 
potently induce receptor degradation and as a result to more 
potently sinergize with the BRAF/MEK inhibitors in tumor 
growth impairment and induction of apoptosis.
RESULTS
ErbB3 receptor is rapidly phosphorylated in a 
broad panel of BRAF-mutated melanoma cell lines 
upon exposure to a BRAF or to a MEK inhibitor
We and others have recently shown that the 
ErbB3 receptor is involved in the activation of an early 
Oncotarget24825www.impactjournals.com/oncotarget
feedback survival loop upon cell exposure to BRAF and/
or MEK inhibitors [25–27]. Two different mechanisms 
have been postulated. In first instance Abel et al [26] 
suggested that BRAF mutated melanoma cell lines, 
when exposed to a BRAF inhibitor, undergo rapid 
increase of ErbB3 mRNA transcription/translation 
(1.5- to 3-fold) which makes cells more sensitive to 
stimulation by exogenously added ligand Neuregulin-1 
(HRG or NRG1). In contrast to this finding we observed 
in three cell lines with different BRAF V600 mutations, 
namely MST-L, LOX-IMVI and WM266, that cell 
exposure to either vemurafenib as BRAF inhibitor or 
trametinib as MEK inhibitor, does not lead to increase 
ErbB3 protein expression but instead causes increased 
spontaneous phosphorylation of ErbB3 (several-fold) 
[27]. In one cell line we showed that this is consequent 
to increased endogenous production of NRG1 and 
activation of an autocrine loop [27].
In order to confirm and expand our previous 
observations we conducted an extensive analysis of a 
larger panel of 11 BRAF-mutated melanoma cell lines 
indicated in Table 1. In all cell lines we initially assessed 
the level of expression of all ErbB receptors and found 
that in all of them, ErbB3 was constantly expressed at 
high levels with the exception of M263 cells. In contrast 
all other ErbB receptors were expressed at variable 
levels with ErbB1/EGFR and ErbB4 showing low or 
undetectable levels in several cells.
Cell extracts of the 8 new melanoma cell lines M14, 
A375, SK-Mel5, M262, M263, M229, M397 and WM115 
exposed to vemurafenib and/or trametinib were prepared 
and subjected to western blotting. The results, summarized 
in Table 1, show that in the majority of cell lines ErbB3 
undergoes a strong upregulation of its phosphorylation 
in the absence of external addition of NRG1 upon 
exposure to vemurafenib or trametinib or both drugs. 
Table 1: ErbB3 receptor is phosphorylated in a panel of BRAF-mutated melanoma cell lines upon 
exposure to a vemurafenib and/or trametinib.
Cell line ErbB1 ErbB2 ErbB3 ErbB4 Activation of 
pErbB3 by 
BRAFi and 
vemurafenib 
IC50
Activation of 
pErbB3 by 
MEKi and 
trametinib 
IC50
M14 (V600E) 0 70% 71% 47% + / 0.35 μM + / 0.21 μM
LOXIMVI 
(V600E) 2% 42% 71% 78% + / 0.15 μM + / 0.11 μM
A375 (V600E) 70% 1% 1% 49% + / n.d. + / n.d.
SK Mel5 
(V600E) 29% 38, 1% 42, 1% 93, 7% + / n.d. − / n.d.
M262 (V600E) 2% 15% 47% 11% + / 0.2 μM + / n.d.
M263 (V600E) 0 1% 10% 0 − / n.d. − / n.d.
M229 (V600E) 0 28% 97% 1% + / 0.3 μM + / n.d.
M397 (V600E) 0 7% 79% 0 + / n.d. + / n.d.
WM266 
(V600D)
33% 66% 68% 60% + / 0.16 μM + / 0.1 μM
WM115 
(V600D)
9% 34% 51% 14% + / n.d. + / n.d.
MST-L (V600R) 1% 9% 39% 48% + / 0.26 μM + / 0.17
Flow cytometry analysis of ErbBs membrane expression in a panel of 11 melanoma cell lines. The percentage of positive 
cells was determined by staining with the indicated primary antibodies and with the isotype-matched andibodies as 
negative control. ErbB3 is constantly expressed at high levels with the exception of M263 cells. Cell extracts from 
these cell lines exposed to vemurafenib and/or trametinib were prepared and subjected to western blotting. The results 
summarized in this Table show that ErbB3 is activated in 10 out of 11 cell lines evaluated upon cells exposure to drugs. 
The IC50 values relative to vemurafenib or trametinib was assessed through in vitro proliferation assays as described in the 
materials and methods section.
Oncotarget24826www.impactjournals.com/oncotarget
Detailed results of three positive cell lines (A375, M229 
and WM115) are shown in Figure 1. Notably, feedback 
activation of pErbB3 is accompanied by strongly increased 
phosphorylation of AKT (Figure 1). In summary, while 
we observed upregulation of ErbB3 phosphorylation in 10 
out of 11 cell lines, we did not observe any significant 
increase in ErbB3 protein levels in agreement with our 
previous report [27]. In order to further investigate this 
aspect we carried out qPCR analysis of ErbB3 and NRG1 
mRNA levels in the “positive” cell lines after exposure to 
vemurafenib. The results (Supplementary Table S1) show 
that ErbB3 mRNA levels remain substantially unchanged, 
whereas NRG1 mRNA levels constantly increase from a 
minimum of 1.7-fold to a maximum of 7-fold in all cells 
analyzed. We also determined whether vemurafenib plus 
trametinib is able to induce NRG1 transcription in the 
three cell lines of Figure 1. The results (Supplementary 
Figure S1), show that also the combination treatment 
is able to induce autocrine NRG1 production albeit at 
variable levels in the various cell lines. Incidentally, A375 
cells present the highest amplitude of NRG1 induction and 
also show the strongest degree of AKT phosphorylation.
It has been recently reported that EPHA2 
is involved in the establishment of resistance to 
vemurafenib via upregulation of its expression and 
increased levels of S897 phosphorylation [32, 33]. 
EPHA2 S897 hyperphosphorylation in resistant cells 
is mediated by AKT [32]. Hence, we decided to 
assess whether also in sensitive cell lines AKT S473 
hyperphosphorylation following short term treatment 
with BRAFi and/or MEKi correlated with increased 
levels of S897 EPHA2. Surprisingly, in sensitive cells 
(Supplementary Figure S2) EPHA2 S897 is shut off at 
the same time S473 AKT is upregulated. This finding 
suggests that EPHA2 is not involved in the early adaptive 
survival loop downstream to ErbB3.
In order to assess whether anti-ErbB3 monoclonal 
antibodies are capable of inhibiting vemurafenib and 
trametinib upregulation of pErbB3 and pAKT, cells were 
simultaneously exposed to treatment combinations with 
anti-ErbB3 antibody A3 and cell extracts subjected to 
Western blotting. The results (Supplementary Figure S3) 
show, as expected, that A3 is able to partially but 
reproducibly decrease vemurafenib/trametinib-induced 
activation of the pErbB3/pAKT pathway.
ErbB3 mAbs inhibit the establishment of 
resistance and restore drug sensitivity to 
vemurafenib resistant melanoma cells
A critical issue in the management of BRAF 
mutated melanoma is the development of resistance to 
Figure 1: Vemurafenib and/or Trametinib treatments induce selective ErbB3 phosporylation and AKT activation in 
melanoma cells. A375, M229 and WM115 cells were serum starved for 24 h, treated or not with vemurafenib (0.3 μM), with trametinib 
(0.15 μM) or with their combination for 24 h. Western blot analysis performed using the indicated antibodies shows that both vemurafenib 
and trametinib induce a strong phosphorylation of ErbB3 (Y1289) and AKT (S473). For densitometric analysis results are expressed as 
mean values from three independent experiments.
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BRAF inhibitors [33]. In most cases resistance has been 
linked to the reactivation of the MAPK/ERK pathway as 
consequence to secondary mutations or altered protein 
expression and it has been shown that these cells can still 
be growth-impaired by MEK kinase inhibitors both in 
vitro and in the clinic [17, 35].
We sought initially to generate cells resistant either 
to vemurafenib or to the combination of vemurafenib 
plus one of our anti-ErbB3 mAbs by exposing WM266 
cells to growing concentrations of vemurafenib. As 
shown in Figure 2A, while we were able to select cells 
resistant to vemurafenib, long term co-treatment with 
combination of vemurafenib (at the initial concentration 
of 50 nM) and of the anti-ErbB3 antibody A3 (at the 
concentration of 10 μg/ml) always resulted in a strong 
decrease in cell viability and in visible stress-induced 
changes in cell morphology (see Figure 2 rightmost 
panel) which did not allow to continue the selection 
process after 1–2 weeks of culture. Of notice, treatment 
of cells with A3 alone did not induce any significant 
effect on cell viability (data not shown). This experiment 
was repeated at least three times also with a different 
anti ErbB3 antibody with similar results. Hence we 
can conclude that blocking ErbB3 together with BRAF 
strongly affects the development of de novo resistance.
On the other hand, using growing concentrations 
of vemurafenib up to 10 μM we were able to obtain a 
population of cells resistant to this drug. We used these 
cells to analyze ErbB3 expression and activation, and 
whether anti-ErbB3 antibodies could still be able to 
synegize with trametinib.
Total protein extracts of WM266 resistant 
cells exposed to A3, vemurafenib and/or trametinib 
were subjected to Western Blot analysis. The results 
(Figure 2B) show that these cells maintain the ability to 
undergo pErbB3 activation upon short term exposure to 
trametinib and that this is abolished by co-treatment with 
the A3 mAb. Importantly, A3 treatment in combination 
vemurafenib and trametinib in resistant cells is able to 
further reduce pERK activation.
In addition, in vitro colony formation assays were 
carried out on WM266 resistant clones in the presence 
of growing concentrations of vemurafenib alone or in 
combination with A3 and/or trametinib. Our results clearly 
show that, while treatment of vemurafenib resistant cells 
with either trametinib (at a greater extent) or A3 (at a 
lower extent) is able to partially restore cell sensitivity to 
vemurafenib, only the co-treatment of the resistant clones 
with both trametinib and A3 is able to fully restore cells 
sensitivity to vemurafenib (Figure 2C, right panel). The 
results described above led us to postulate that suppressing 
the RAS-RAF-MAPK pathway at multiple levels in 
combination with anti-ErbB3 mAbs is able to control and 
reduce cancer growth for a longer time by inhibiting the 
early and the long-term adaptive mechanisms centered 
around ErbB3.
Combination of two anti-ErbB3 mAbs 
binding different surface epitopes strongly 
inhibits melanoma cell growth and receptor 
internalization and degradation
It has been previously shown that combining pairs 
of anti-ErbB mAbs recognizing distinct epitopes in the 
extracellular domain exerts a superior antitumor effect 
compared to the use of individual antibodies because 
of their ability to inhibit receptor recycling [31, 36]. 
We therefore assessed the effect of the two anti-ErbB3 
antibodies A3 and A4. We have previously shown that 
both antibodies inhibit NRG1 binding, NRG1-induced 
pHER3 stimulation, ligand-induced signaling and 
ligand-induced melanoma cell proliferation through 
binding to different epitopes [29, 30], one of which (A3) 
has been mapped to the ErbB3 heterodimerization loop 
with other ErbBs.
For this purpose we used MST-L cells which 
are known to be growth stimulated upon exposure 
to exogenous NRG1. First of all we compared the 
proliferative response of MST-L melanoma cells pre-
treated with each mAb alone or their combination and then 
incubated with NRG1 (HRG) for 48, 72 and 96 h in the 
presence of the mAbs. After incubation, cells were fixed 
and stained with anti-Ki67 antibodies to identify cycling 
cells. Quantitative analysis of the percentage of cells 
presenting Ki67-positive nuclei indicated that the increase 
of the proliferation rate, clearly evident upon 48, 72 and 
96 h of NRG1 stimulation, was strongly and significantly 
inhibited by the mAbs combination compared to single 
treatment with either A3 or A4 mAbs individually. 
Melanoma cell growth inhibition induced by mAbs 
combination compared to single mAbs was particularly 
pronounced after 96 h of treatment (Figure 3A).
In order to confirm these data, we performed in vitro 
colony formation assays in the presence of growing 
concentrations of A3 and A4 alone or in combination for 
ten days. Remarkably A3 + A4 combination was able to 
better inhibit MST-L melanoma cells growth compared to 
the single treatments (Figure 3B).
Since we have previously demonstrated that A3 and 
A4 mAbs are able to potently induce ErbB3 internalization 
and degradation by inducing receptor relocalization to 
the endocytic lysosomal degradative pathway [29], we 
decided to investigate if mAbs combination might be more 
effective compared to single treatments. In order to clarify 
this aspect MST-L cells were treated with A3, A4 or with 
A3 + A4 for 1 h at 37°C in the presence of LysoTracker-
Red to identify the lysosomal compartment. Quantitative 
immunofluorescence analysis demonstrated colocalization 
of ErbB3-bound A3, A4 and A3 + A4 with the LysoTracker 
marker in intracellular, perinuclear dots corresponding to 
lysosomes, according to our previous data [29]. Moreover, 
we clearly observed that the mAbs combination is able to 
strongly accelerate receptor relocalization to the lysosomal 
Oncotarget24828www.impactjournals.com/oncotarget
Figure 2: Anti-ErbB3 mAbs restore drug sensitivity to vemurafenib in resistant melanoma cells. WM266 human melanoma 
cells were treated for about two months with increasing drug concentrations every two weeks (from 50 nM to 10 μM) in order to generate 
vemurafenib resistant cells. A. Magnifications of cells show that the combination of vemurafenib (at the initial concentration of 50 nM) 
with the anti-ErbB3 antibody A3 (at the concentration of 10 μg/ml) decreases cell viability compared to untreated (Unt) or vemurafenib-
treated (Vem) after two week of treatment. The pictures shown are representative of three indipendent experiments. B. WM266 melanoma 
cells resistant to vemurafenib (WM r) were serum starved and treated with vemurafenib (0.3 μM), with trametinib (0.15 μM) or with their 
combination in presence or not of anti-ErbB3 mAb A3 (20 μg/ml) for 24 h. Western blot analysis shows that A3 mAb abrogate ErbB3 
phosphotylation (Y1289) as well as the strong increase of pAKT (S473) induced by trametinib in vemurafenib resistant WM266 cells 
(WM r). WM266 wild type cells (WM wt) were used as positive control. For densitometric analysis results are expressed as mean values 
from three independent experiments. C. WM r cells were grown in the presence of different doses of vemurafenib and combined or not 
with trametinib (0.15 μM), A3 mAb (20 μg/ml) or their combination for 10 day. Cells were stained with crystal violet and then dissolved 
in a Methanol/SDS solution and the adsorbance (595 nm) was read using a microplate ELISA reader. Quantitative analysis for curve fitting 
and for IC50 evaluation, performed by KaleidaGraph software, shows that either trametinib (at a greater extent) or A3 (at a lower extent) 
are able to partially restore cell sensitivity to vemurafenib, but only the co-treatment of the resistant clones with both molecules is able to 
fully restore cells sensitivity to vemurafenib. IC50 Vem WM wt = 0.16 μM; IC50 Vem WM r = 7 μM; IC50 Vem WM r + Tram = 0.77 μM; 
IC50 Vem WM r + A3 = 3 μM; IC50 Vem WM r + Tram + A3 = 0.1 μM. p-values were calculated using Student’s t test and significance 
level has been defined as p < 0.05. For IC50 Vem WM r + Tram + A3 p < 0.001 vs IC50 Vem WM r cells. For IC50 Vem WM r + Tram 
p < 0.05 vs IC50 Vem WM r cells. For IC50 Vem WM r + A3 NS vs IC50 Vem WM r. WM wt were used as control.
C
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Figure 3: Combination of anti-ErbB3 mAbs is more effective in inhibiting melanoma cell growth compared to the single 
treatments. A. MST-L cells were pre-treated with each mAb or their combination and then incubated with NRG1 (HRG) for 48, 72 and 96 h in 
the presence of the antibodies, fixed and stained with anti-Ki67 antibodies to identify cycling cells. Quantitative analysis of the percentage of cells 
presenting Ki67-positive nuclei was performed as reported in materials and methods and values are expressed as mean values ± standard errors 
(SE). Student’s t test was performed and significance level has been defined as described in materials and methods. The increase of the proliferation 
rate upon 48, 72 and 96 h of NRG1 stimulation is inhibited either by mAbs combination and A3/A4 individually. Cell growth inhibition induced 
by mAbs combination is particularly pronounced after 96 h of treatment comapred to single mAbs. *p < 0.05 vs. the corresponding NRG1-treated 
cells, **p < 0.001 vs. the corresponding HRG-treated cells. Bar = 10 μm. B. MST-L cells were grown in the presence of different doses A3 and A4 
alone or in combination for 10 days. Cells were then fixed and stained with crystal violet (upper part). Cells were then dissolved in a Methanol/SDS 
solution and the adsorbance (595 nm) was read using a microplate ELISA reader. Quantitative analysis for curve fitting and for IC50 evaluation, 
performed by GraphPad software, shows that A3 and A4 combination is able to inhibit melanoma cell growth better than the single treatments. 
EC50 A3 = 38 μg/mL; EC50 A4 = 35 μg/mL; EC50 A3 + A4 = 7 μg/mL. The Combination Index (CI) evaluation, performed by CalcuSyn 
software as reported in materials and methods, indicate that A3 and A4 are synersistic drugs; CI = 0.7.
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compartment compared to single mAbs, especially after 
short treatments (Figure 4A, arrows). In order to verify 
whether the accelerated ErbB3 redistribution to the 
endocytic degradative pathway induced by A3 and A4 
combination would actually correspond to more efficient 
and rapid receptor degradation compared to single 
treatments, we performed Western Blot analysis. Results 
(Figure 4B) show a dramatic decrease of the ErbB3 signal 
already after 30 minutes and 1 h of treatment with the A3 
+ A4 combination compared to single treatments. It is of 
interest to notice that also after 48 h only the combined 
treatment with A3 + A4 is able to maintain persistent 
downregulation of ErbB3.
Finally, in order to identify the mechanism 
responsible for mAbs-induced ErbB3 internalization 
we treated MST-L cells with NRG1, A3 or A4 for 
different time points and subjected total protein extracts 
to immunoprecipitations with an antibody directed 
against the ErbB3 receptor. Western Blot analysis 
using anti-UBI antibodies showed that A3 and A4 
induce strong ErbB3 receptor ubiquitination after 30 
minutes of treatment compared to NRG1 stimulation 
(Supplementary Figure S4a). To further demonstrate 
the involvement of the ubiquitination process in mAbs-
induced receptor internalization we exposed MST-L cells 
to the ubiquitination-inhibitor PYR-41 and then to A3, 
A4 or NRG1. To evaluate the amount of ErbB3 receptors 
that remained localized on the plasma membrane upon the 
treatments described above, internalization experiments 
were performed. The plasma membranes were visualized 
by incubating the cells with the lipophilic tracer Vybrant 
DiI at 4°C before fixation. Immunofluorescence analysis 
showed that, PYR-41 pre-treatment was able to block 
mAbs and ligand-induced receptor internalization 
(Supplementary Figure S4b). Moreover, PYR-41 pre-
treatment inhibited mAbs-induced ErbB3 degradation 
and ubiquitination as showed by Western Blot and 
immunoprecipitation analysis in Supplementary Figure 
S4c and S4d.
Anti-ErbB3 mAbs combination with 
vemurafenib and/or trametinib inhibits 
proliferation and induces apoptosis better than 
single antibody treatments
We next assessed whether the combination of the 
anti-ErbB3 antibodies A3 and A4 is more potent than 
single antibody treatment to block vemurafenib-induced 
activation of the pErbB3/pAKT axis and to synergize with 
vemurafenib in the inhibition of melanoma cell growth. 
Total protein extracts of M14 cells exposed to A3, A4 
and vemurafenib individually or in combination were 
subjected to Western Blot analysis. The results (Figure 5A, 
left panel) clearly showed that while A3 and A4 alone 
were able to partially inhibit vemurafenib-induced pErbB3 
and pAKT activation, only their combination was able to 
completely abrogate receptor activation and downstream 
signaling. Notably, we observed that the triple combined 
treatment leads to a complete abrogation of pERK.
In order to assess whether inhibition of pErbB3 and 
pAKT could result in potentiation of the growth inhibitory 
effects of vemurafenib, in vitro colony formation assays 
were carried out in the presence of growing concentrations 
of vemurafenib alone, in combination with A3 or A4 or 
with both the mAbs. Treatment with both anti-ErbB3 
mAbs vs single mAb treatment strongly potentiated 
growth inhibition by vemurafenib (12-fold vs 3-fold) 
at all doses of the BRAF inhibitor. The same findings 
were confirmed in the WM266 melanoma cell line 
(Supplementary Figure S5).
Since we have previously demonstrated that the 
ErbB3-dependent feedback survival loop is activated 
also by MEK inhibitors [27], we decided to test the anti-
ErbB3 mAbs combination with trametinib. To this purpose 
we performed Western Blot analysis and in vitro colony 
formation assays as described above. As expected also the 
mAbs combination with trametinib completely abrogated 
MEK inhibitor-induced ErbB3 and AKT activation 
(Figure 5B, left panel). Moreover the triple combinations 
resulted had a stronger impact on melanoma cells growth 
compared to double treatments (11-fold vs 3-fold). 
Finally when cells were treated with suboptimal doses of 
vemurafenib and trametinib, the addition of A3 and A4 
mAbs combination was capable to provide a powerful 
synergistic inhibition of cell growth (Figure 5C).
In order to provide further insights into the biological 
effect of mAbs combination with vemurafenib or trametinib 
we evaluated apoptosis induction by flow cytometry in M14 
melanoma cells. Consistently, in cells treated with triple 
combinations we observed an increased percentage of cells 
undergoing apoptosis after 48 hours of treatment compared 
to single and double treatments (Figure 6A and 6B, left 
panels). Importantly when we treated M14 melanoma cells 
with the quadruple combination (vemurafenib, trametinib, 
A3 and A4) we observed a powerful synergistic apoptosis 
induction (Figure 6C). Moreover, cell cycle analysis 
showed that, while vemurafenib or trametinib treatments 
were characterized by a G0/G1 arrest in line with previous 
literature reports [37, 38], combination of A3 and A4 + 
either vemurafenib or trametinib caused primarily a block 
in S-phase (Figure 6A and 6B, right panels), suggestive of 
the activation of a DNA damage checkpoint. In order to 
investigate this aspect further, M14 melanoma cells exposed 
to A3, A4 and vemurafenib alone or their combinations and 
subjected to Western Blot analysis for a set of cell cycle 
markers (Figure 6D). Results clearly showed that, while 
treatment with vemurafenib was accompanied by strong 
activation of p27 in line with the G0/G1 block, co-treatment 
with vemurafenib and A3 + A4 caused a dramatic reduction 
of CDK4 and Cyclin D1, while inducing a strong increase 
of phosphorylated histone H3 and of gamma-H2AX 
phosphorylation (pH2AX), thus confirming the occurrence 
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of DNA damage. Of note, similar results were obtained with 
mAbs combination with trametinib.
Anti-ErbB3 mAbs combination strongly inhibits 
“in vivo” melanoma cell growth and reduces 
tumor relapse when combined with vemurafenib 
and trametinib
We next assessed the effect of the anti-ErbB3 
antibodies A3 and A4 on melanoma cell growth in vivo.
Firstly we compared the efficacy of single treatment 
with vemurafenib or with trametinib with that of the 
combination of A3 + A4. Mice were injected s.c. with 
1 × 106 M14 cells. When tumors reached the size of 
100 mm3 mice were randomly divided into four different 
groups of 6 mice and subjected to treatments for five 
weeks. Tumor growth was measured once/weekly. Our 
data (Supplementary Figure S6A and S6B) showed the 
capability of the anti ErbB3 antibodies mAbs to partially 
inhibit melanoma cells growth also in vivo.
Figure 4: Combination of anti-ErbB3 mAbs is more effective in inducing receptor internalization and degradation.  
A. MST-L cells were treated with A3, A4 or their combination for 30′ and 1 h at 37°C in the presence of LysoTracker-Red as reported in 
materials and methods. Quantitative immunoflorescence analysis of the percentage of colocalization of signals and 3D reconstruction was 
performed as described in materials and methods. Results are expressed as mean values ± SE (standard errors): the percentage of colocalization 
was calculated analyzing a minimum of 50 cells for each treatment randomly taken from three independent experiments. Student’s t-test was 
performed and significance level has been defined as described in materials and methods. A colocalization of ErbB3-bound A3, A4 and their 
combination with the LysoTracker marker in intracellular, perinuclear dots corresponding to lysosomes is evident. mAbs combination strongly 
accelerate receptor targeting to the lysosomal compartment compared to single treatments. **p < 0.001 vs. the corresponding A3 or A4-treated 
cells; the slight increase of colocalization of combination compared to single treatments at 1 h is not significant. Bar = 10 μm. B. Western blot 
analysis using anti-ErbB3 polyclonal antibodies in MST-L cells treated with A3, A4 or their combination at 37°C for the different time points 
(0.5, 1, 48 h). A drastic decrease of the band corresponding to ErbB3 is evident after mAbs combination treatments compared to single mAbs. 
The equal loading was assessed with anti-actin antibody and densitometric analysis was performed as described in materials and methods.
Oncotarget24832www.impactjournals.com/oncotarget
Figure 5: Anti-ErbB3 mAbs combination counteracts the increase of receptor phosphorylation and potentiate growth 
inhibition induced by vemurafenib and trametinib better than the single mAbs. M14 melanoma cells serum starved and 
treated with vemurafenib (0.3 μM) A. left part or trametinib (0.15 μM) B. left part) for 24 h were incubated with 20 μg/ml of anti-ErbB3 
mAbs A3, A4 or their combination. Western blot analysis shows that only mAbs combination completely abrogates receptor phosphorylation 
(Y1289) and ATK signaling (S473). For densitometric analysis results are expressed as mean values from three independent experiments. 
M14 cells were grown in the presence of different doses of vemurafenib A. right part or trametinib B. right part alone or in combination 
with 20 μg/ml of anti-ErbB3 mAbs A3, A4 or their combination for 10 days. Cells were then treated as described above. Quantitative 
analysis, performed by KaleidaGraph software as described above, shows that the combination of A3 and A4 enhances the inhibitory effect 
of vemurafenib and trametinib on cell growth better than the single mAbs. IC50 vem = 0.35 μM; IC50 vem + A3 = 0.11 μM; IC50 vem + A4 
= 0.08 μM; IC50 vem + A3 + A4 = 0, 03 μM. IC50 tram = 0.21 μM; IC50 tram + A3 = 0.08 μM; IC50 tram + A4 = 0.07 μM; IC50 tram + A3 
+ A4 = 0.02. Results are reported as mean values ± standard deviation (SD) from three independent experiments. p-values were calculated 
using Student’s t test and significance level has been defined as p < 0, 05. For IC50 vem + A3, IC50 vem + A4, IC50 tram + A3 and IC50 
tram + A4 p < 0, 001 vs IC50 vem and IC50 tram respectively. For IC50 vem + A3 + A4 and IC50 tram + A3 + A4 p < 0, 0001 vs IC50 vem 
and IC50 tram respectively. C. Cells were treated with suboptimal doses of vemurafenib and/or trametinib alone or in combination with 
A3 and/or A4 mAbs. The in vitro colony formation assay shows that the addition of mAbs combination inhibits cells growth better than the 
single mAbs. *p < 0, 01 vs untreated cells; **p < 0, 001 vs untreated cells; NS vs untreated cells.
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Figure 6: Anti-ErbB3 mAbs combination induces melanoma cell apoptosis better than the single mAbs when combined 
with vemurafenib and/or trametinib. M14 melanoma cells treated with vemurafenib (1 μM) A. left part or trametinib (0.5 μM) 
B. left part for 48 h were incubated with 20 μg/ml of anti-ErbB3 mAbs A3, A4 or their combination. Apoptosis induction, evaluated by 
FACS analysis, shows that the combination of A3 and A4 enhances the apoptotic effect of vemurafenib and trametinib better than the single 
mAbs. *p < 0, 01 vs untreated cells; **p < 0, 005 vs untreated cells; ***p < 0, 001 vs untreated cells; NS vs untreated cells. M14 cells 
treated as above for 24 h were assayed for cell cycle analysis by FACS. The results A and B. right parts show that combination of A3 and 
A4 + either vemurafenib or trametinib causes primarily a block in S-phase. C. Cells were treated with suboptimal doses of vemurafenib 
and/or trametinib alone or in combination with A3 and/or A4 mAbs for 48 h. The apoptosis induction, evaluated as above, shows that the 
addition of mAbs combination enhances the apoptotic effect of the drugs better than the single mAbs. *p < 0, 01 vs untreated cells; **p < 
0, 001 vs untreated cells; NS vs untreated cells. *p < 0, 01 vs untreated cells; **p < 0, 005 vs untreated cells; ***p < 0, 001 vs untreated 
cells. D. M14 cells serum starved and treated with vemurafenib (1 μM) for 24 h were incubated with 20 μg/ml of anti-ErbB3 mAbs A3, A4 
or their combination. Western blot analysis shows that co-treatment with vemurafenib and A3 + A4 causes a reduction of CDK4 and Cyclin 
D1 and an increase of the phosphorylation of histone H3 and gamma-H2AX.
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Gadiot et al [39] have recently compared the 
efficacy in vivo of single treatment of mutant BRAF 
melanoma with vemurafenib alone, trametinib alone or 
the combination of vemurafenib and trametinib. While 
vemurafenib alone was able to control tumor growth only 
for a short period of 3–4 weeks after which relapses occur, 
the combination of vemurafenib and trametinib was able 
to control cancer growth for a longer time. However, also 
in these cases, mice were not cured because tumors started 
to regrow soon after discontinuation of treatment. This 
mirrors exactly what happens in the clinic. We decided, 
therefore, to evaluate if combination treatments using 
anti-ErbB3 mAbs would be able to significantly improve 
long term survival and better control disease relapse. 
In order to investigate these aspects we carried out a 
second in vivo study where we compared the efficacy of 
the combination vemurafenib + trametinib, with that of 
vemurafenib + trametinib + A3 and A4. The results are 
shown in Figure 7A panel a. In both groups melanoma 
cell growth was strongly impaired in a comparable 
manner, even though the presence of the antibodies 
showed a modest but not significant trend to superiority. 
Interestingly, however, when we stopped treatments, while 
the quadruple combination group showed an evident 
and durable control of tumor growth, the vemurafenib/
trametinib group tumors grew up rapidly. In order to better 
understand the mechanism at the basis of the differences 
in the rate of tumor regrowth between these two groups 
of mice pathology analysis was carried out. The results 
(Figure 7B and Table 2) show that tumors from mice 
treated by vemu + tram + A3 + A4 are characterized 
almost exclusively by large necrotic areas (> 80%) with 
small residual areas of tumor growth. In contrast in tumors 
from mice treated by vemu + tram vital areas predominate. 
Differences between the two groups are highly statistically 
significant (p = 0.004). Furthermore the residual vital areas 
in the quadruple treatment group show a lower degree of 
proliferation.
Moreover the quadruple treatment with vemurafenib 
+ trametinib + A3 + A4 did not induce higher toxicity over 
the combination of vemurafenib + trametininb as shown 
by serial body weight measurements over the course of the 
study (see Supplementary Figure S7).
Finally to assess the short term effect of in vivo 
treatments we carried out the following pharmacodynamic 
study. Mice with M14 tumors grown subcutaneously up 
to the size of 1 cm3 were treated with a single dose of 
the vemurafenib + trametinib combination or with the 
quadruple combination vemurafenib + trametinib + 
A3/A4. After 24 hours mice were euthanized, tumor 
collected total protein extracts analyzed by Western Blot. 
The results shown in Figure 7C indicate that the strong 
activation of pErbB3 and pAKT following vemurafenib/
trametinib treatments was evident also in vivo and was 
completely abrogated by A3 and A4. Moreover the 
quadruple combination resulted in a strong inhibition of 
pERK signaling and in the cleavage of PARP, a marker 
of apoptosis (Figure 7C). Of note, we subjected the total 
protein extracts from tumors treated with vehicle or 
vemurafenib + trametinib to an RTK array to detect early 
changes in the phosphorylation level of approximately 
fifty RTKs. According to our previous data [27] we found 
that, while the phosphorylation level of most receptors, 
including also PDGFR and IGF1R remained unchanged or 
underwent minor variations, ErbB3 phosphorylation was 
prominently increased (Supplementary Figure S8). These 
data strongly underline the role of ErbB3 in the rebound of 
melanoma cell growth following vemurafenib/trametinib 
treatments and pave the way for the use of anti-ErbB3 
mAbs as adjuncts to current therapies in order to obtain a 
durable control of tumor growth.
DISCUSSION
Therapy of patients with metastatic melanoma 
has significantly improved over the past years thanks to 
the introduction of several targeted terapies; however, 
there is still need for substantial improvements. This is 
particularly clear in the case of patients bearing mutations 
in the BRAF oncogene where the initial introduction of 
BRAF inhibitors, although capable of inducing impressive 
objective responses in approximately 50% of patients, 
extended progression free survival (PFS) only up to 
5–6 months from the historical 2.5 months previously 
obtained with dacarbazine [40]. In this set of patients 
PFS has been further improved to reach approximately 
10 months when a BRAF inhibitor is combined with a 
MEK inhibitor [18–20]. However, disease relapses also 
in these cases constantly occur because of the emergence 
of drug resistance, a phenomenon that has been the object 
of intensive speculations also in the case of other highly 
selective oncogene kinase inhibitors [41]. Initial analysis 
of the genetic lansdscape of mutations occurring in 
patients exposed to both BRAF and MEK inhibitors, has 
unveiled a highly complex scenario involving multiple 
genes and factors responsible for the reactivation of 
the MAPK pathway [42]. It is virtually impossibile to 
envisage a therapy directed to inhibit all these targets 
simultaneously. Hence we are far away from the complete 
control of this aggressive disease and alternative strategies 
are required to tackle this issue.
The present study is directed to provide an additional 
option in this direction using a different approach. It has 
been previously observed that in oncogene addicted 
melanoma cells some important compensatory survival 
pathways are being kept under check [9, 34, 42]. These 
pathways are feedback-reactivated once cells are exposed 
to inhibitors of the original oncogene, and their reactivation 
heavily contributes to the failure of the initial therapy. 
Identification of pivotal compensatory pathways and of 
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Figure 7: Anti-ErbB3 mAbs combination reduces tumor relapse when combined with vemurafenib and trametinib.  
A. M14 melanoma cells were subcutaneously injected in immunodeficient mice at 1 × 106 cells/mouse. Treatments started when tumors 
reached a 100 mm3 volume and mice were allocated six per group. Mice were treated with vehicle, vemurafenib (25 mg/kg) and trametinib 
(0, 5 mg/kg) alone or in combination with A3 and A4 mAbs (10 + 10 mg/kg) for four weeks. Tumor growth was measured once/weekly. 
The results show that the quadruple combination group is characterized by a durable control of tumor growth. *p < 0, 01 vs vehicle-treated 
mice; **p < 0, 005 vs vehicle-treated mice. B. Rapresentative images of histology of Vem + Tram-treated mice (left panel) and Vem + Tram 
+ A3 + A4-treated mice (right panel). The quadruple combination-treated ones show a lower percentage of viable areas (asterisk) within 
the tumor mass and larger sheets of coagulative tumor cell necrosis compared to the Vem + Tram-treated tumors (A-B, H&E, original 
magnification x 20) (C-D, insert, H&E, original magnification x 200). C. Mice with M14 tumors grown subcutaneously were treated with 
a single dose of the vemurafenib/trametinib combination or with the quadruple combination vemurafenib + trametinib + A3/A4 for 24 
h. Mice were then euthanized, tumor collected and total protein extracts analyzed by Western Blot. The results show that vemurafenib + 
trametinib induce phosphorylation of ErbB3 (Y1289) and AKT (S473) that is abrogated by anti-ErbB3 mAbs also in vivo.
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their master regulators may offer tremendous opportunities 
to prevent the development of drug resistance. We believe, 
based on our data that one of these master regulators in 
mutant BRAF melanomas, is indeed the ErbB3 receptor. 
This conclusion stems from previous observations by our 
group showing in RTK array studies in three different 
cell lines that ErbB3 is the main RTK undergoing heavy 
phosphorylation in response to exposure to a BRAF or a 
MEK inhibitor [27], and is strengthened in this study in 
which we show in 7 out of the 8 additional BRAF mutated 
cell lines that the same degree of ErbB3 activation takes 
place. Most importantly, also in an in vivo mouse xenograft 
model with one of the new cell lines under study, we 
observe a prominent ErbB3 hyperphosphorylation as 
compared to all other receptors analyzed, which confirms 
the previous in vitro findings. Interestingly, however, in the 
in vivo model additional RTKs undergo phosphorylation 
as compared to in vitro which we believe is the result of 
the contribution of the tumor microenvironment. It has to 
be stressed that in our experiments we do never observe 
increased phosphorylation of other RTKs previously 
reported to be involved in the activation of survival 
pathways in melanoma cells, such as PDGFR and IGF1R 
[11, 14]. We don’t have an easy explanation for this 
discrepancy; a major difference in our experimental model 
is that we analyze RTK changes taking place in the first 
24–48 hours after drug exposure, and not after resistance has 
occurred weeks after cells have been exposed to increasing 
drug concentrations. Hence it is possible that indeed 
ErbB3 is the principal receptor involved in early adaptive 
responses of melanoma cells upon exposure to inhibitors of 
the MAPK pathway. This evidence if further strengthened 
by two other observations. The first being the difficulty to 
generate cells double resistant to a BRAF inhibitor and an 
anti-ErbB3 antibody, at least at the concentrations used in 
this study. The second is the evidence that in cells resistant 
to vemurafenib, the same ErbB3-induced survival loop is 
still present but is activated in this case by a MEK inhibitor. 
Most importantly, its inhibition with an anti-ErbB3 antibody 
rescues completely sensitivity to kinase inhibitors.
What is the mechanism responsible for ErbB3 
hyperphosphoryation? It has been previously proposed that 
BRAF mutated cancer cells either of melanoma or of thyroid 
or of colorectal origin, undergo increased ErbB3 protein 
expression consequent to transcripional activation [25, 26]. 
Various transcriptional regulators have been postulated to 
be responsible for this effect such as increased binding of 
the positive factor FOXD3 in melanoma [26] or decrease 
binding of the negative factor CTBP1 in thyroid cancer [25]. 
In contrast to previous observations our data show in 10/11 
melanoma cell lines that ErbB3 protein levels do not increase 
(both in vitro and in vivo) but that there is instead a selective 
enhancement of its phosphorylation. Extensive RT-PCR 
analysis does not show any detectable increase in ErbB3 
mRNA levels in any of the cells analyzed in contrast with a 
constant increase in the mRNA levels of its ligand neuregulin. 
This finding strengthens our previous observations that 
pointed to the activation of an autocrine survival loop, 
and therefore to a modified tumor microenvironment. In 
the future it will be important to unravel the mechanisms 
at the basis of the increased transcriptional activation of 
the neuregulin gene, because they may offer additional 
opportunities for therapeutic intervention.
The ErbB3 receptor is a potent activator of donw-
stream signaling due to the presence of seven thyrosines in 
its intracytoplasmic domain, which can serve as docking 
sites for PI3K when phosphorylated [43]. ErbB3 activation 
can occur in a variety of ways, which can be distinguished 
in canonical, namely ligand-dependent heterodimerization 
with other receptors of the same ErbB family, in particular 
ErbB2 [44] and non canonical, i.e. through higher order 
and often ligand independent receptor clustering with other 
RTKs, such a cMet, and IGF1R [45, 46]. This complex 
and heterogeneous pattern of activation makes the ErbB3 
receptor particularly resilient to inhibition and challenging 
from the therapeutic standpoint. Since the receptor lacks 
potent intrinsic kinase activity, the most viable approach 
to inhibit its function is through the use of monoclonal 
antibodies [30]. However, also in this case a single 
monoclonal antibody may not be able to fully abrogate 
receptor activity and to exert the most potent therapeutic 
effect. In this paper we use two anti-ErbB3 mAbs directed 
against two different surface epitopes, one capable of 
inhibiting ligand-dependent receptor activation, A3 [28], 
the other, A4, capable of inhibiting both ligand-dependent 
and ligand-independent receptor activation [29, 30]. The 
two antibodies when combined together in vitro show 
increased ability to internalize the receptor and to induce its 
Table 2: Tumors treated with vemurafenib and trametinib show a lower tumor necrosis and tumor 
higher Ki-67 expression compared to tumors treated with the quadruple combination. 
Group Necrosis (%)Mean Value Ki-67 (%)Mean Value
Vem + Tram 61 ± 12.4 79 ± 2, 23
Vem + Tram + A3+A4 82 ± 5.7 71 ± 6, 5
The analysis of tumor necrosis percentage showed a significant difference (p = 0.004) between the tumors treated with Vem + Tram 
(mean value ± standard deviation = 61 ± 12.4; range 40% to 70%) and the tumors treated with Vem + Tram + A3 + A4 (mean value 
± standard deviation = 82 ± 5.7; range 75% to 90%). The mean percentage of Ki-67 expression was 79% (range 75% to 80%) in 
the Vem + Tram-treated tumors and 71% (range 60% to 75%) in the Vem + Tram + A3 + A4 -treated tumors (p = 0.016).
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degradation. We believe the extent and duration of receptor 
degradation is the most useful pharmacodynamic biomarker 
of inhibition. Our results confirm for ErbB3 what has been 
previously shown also for EGFR and ErbB2, i.e. that in 
order to fully inhibit the activity of a receptor of the ErbB 
family a single antibody is not enough and that a superior 
efficacy is achieved both in vitro and in vivo by combining 
two antibodies against distinct epitopes [36, 47, 48]. 
Although clinical translation of this concept is highly 
challenging due to increasing costs of production and to the 
complexity of clinical development, one has to be aware 
that a single antibody for a given target will never be able 
to achieve maximal therapeutic efficacy.
We have been the first to show that activation of 
the ErbB3/AKT axis in melanoma can be inhibited by co-
treatment with anti-ErbB3 mAbs and that these antibodies 
synergize with BRAF and MEK inhibitors in short term in 
vitro clonogenic assays [27]. This was also confirmed by 
others [49]. In this paper we provide strong evidence both 
in vitro and in vivo that addition of anti-ErbB3 antibodies to 
the BRAF/MEK combination, suppresses the development 
of resistance in vitro and potently mitigates disease 
recurrence in vivo. This is in line with the finding that A3 
and A4 also induce further inhibition of pERK, even when 
combined with vemurafenib + trametinib. This finding has 
important clinical implications because Bollag et al [50] 
have demonstrated that profound inhibition of MAPK 
transcriptional output correlates to maximal effectiveness of 
therapy in melanoma patients. Interestingly, in vitro studies 
show that the mechanism of action of anti-ErbB3 antibodies 
differs from that of MEK and BRAF inhibitors and 
dominates in the triple combination regimen. In fact, while 
BRAF and MEK inhibitors block cell cycle progression 
at the G0/G1 level, combination with anti-ErbB3 mAbs 
arrests cells in the S-phase, which suggest the activation 
of a DNA damage checkpoint, further confirmed in vivo 
by strong PARP cleavage. This interesting observation 
may open up to additional synergies with agents capable to 
inhibit DNA repair and which so far have not been taken into 
consideration in melanoma.
Several anti-ErbB3 monoclonal antibodies are under 
development and have been brought to clinical trials for a 
variety of indications such as breast, colorectal and ovarian 
cancers, given the known role of ErbB3 in resistance to 
therapy [30, 51, 52]. In this context, our data warrant the 
use of these antibodies in trials of triple combination with a 
BRAF and a MEK inhibitor with the intent to further improve 
response rates and achieve more durable disease control.
MATERIALS AND METHODS
Cell lines and treatments
Human melanoma cell lines MST-L, WM266, LOX 
IMVI, M14, A375, MALME 3-M, M229, M262, M263, 
M397, WM115 were cultured in RPMI supplemented 
with 10% FBS. To evaluate ErbB3, AKT and ERK 1/2 
signaling and neuregulin (HRG) expression melanoma 
cells were serum starved for 24 h and treated with 
vemurafenib and/or trametinib at different doses and time-
points and incubated or not with 20 μg/ml of anti-ErbB3 
mAbs A4, A3 alone or in combination. To determine the 
effects on melanoma proliferation, seeded at 1 * 105/ well, 
cell lines were treated with increasing concentrations 
(from 0, 002 to 1 μM) of vemurafenib and/or trametinib 
alone or in combination with anti-ErbB3 mAbs for 10 
days. To generate vemurafenib-resistant WM266 human 
melanoma cells, they were treated for about two months 
with increasing drug concentrations every two weeks (from 
50 nM to 10 μM). To analyze the possible internalization 
and degradation of ErbB3, cells were stimulated with 
HRG at 100 ng/ml or incubated with A3, A4 alone or in 
combination at 37°C for different time as indicated. For the 
visualization of the cell surface, plasma membranes were 
labeled with Vybrant DiL cell labeling solution for 1 h at 
4°C before fixation. To induce LysoTracker internalization, 
cells were incubated with LysoTracker-Red for 1 h at 
37°C and then fixed. For proliferation assays, cells were 
incubated with the anti-ErbB3 monoclonals for 1 h at 37°C 
and then stimulated with 30 ng/ml HRG for 48 or 72 h.
Antibodies and reagents
Antibodies against AKT, ERK 1/2, phospho-ErbB3 
(Y1289), phospho-AKT (S473), phospho-ERK 1/2 
(T202/204), anti-pH2A.X, anti-pH3 and anti-cleaved-PARP 
were purchased from Cell Signaling Technology. Anti-ErbB3, 
anti-P27, anti-Cyclin D1, anti-CDK4, anti-UBI and anti-
GAPDH were obtained from Santa Cruz Biotechnology. Anti-
rabbit and anti-mouse were purchased from AbCam. Anti 
ErbB3 antibodies A3 and A4 have been described previously 
[28–30]. The two anti-ErbB3 antibodies are all of the IgG1 
isotype (EM unpublished observation). Vemurafenib and 
trametinib were obtained from Selleck Chemicals. TaqMan 
probes for ErbB3, NRG1 and housekeeping gene 18S were 
purchased from Applied Biosystems. The rabbit anti-Ki67 
polyclonal antibodies were from Zymed Laboratories. FITC-
conjugated goat anti-mouse IgG was obtained from Cappel 
Research Products. Texas Red-conjugated goat anti-rabbit 
IgG were from Jackson Immunoresearch Laboratories. DAPI 
was purchased from Sigma. Vybrant DiI cell labeling solution 
was from Invitrogen. LysoTracker-Red was obtained from 
Molecular Probes.
Immunofluorescence analysis
Melanoma cells, grown on coverslips and incubated 
with the monoclonals A3, A4 alone or in combination and/or 
stimulated with HRG were fixed with 4% paraformaldehyde 
in PBS for 30 min at 25°C followed by treatment with 0.1 
M glycine for 20 min at 25°C and with 0.1% Triton X-100 
for an additional 5 min at 25°C to allow permeabilization. 
To evaluate cell proliferation, cells were then incubated for 
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1 h at 25°C with the rabbit anti-Ki67 polyclonal antibodies. 
The primary antibodies were visualized using goat anti-
mouse IgG-FITC and goat anti-rabbit IgG-Texas Red for 30 
min at 25°C. To induce LysoTracker internalization, cells 
were incubated with LysoTracker-Red for 1 h at 37°C and 
then fixed. Nuclei were stained with DAPI. Coverslips were 
finally mounted with mowiol for observation. To assess 
the extent of colocalization of fluorescence signals, cells 
were scanned in a series of 0.5 μm sequential sections with 
an ApoTome System (Zeiss) connected with an Axiovert 
200 inverted microscope (Zeiss); image analysis was then 
performed by the Axiovision software and 3D reconstruction 
of a selection of three central out of the total number of the 
serial optical sections was shown in each figure. Quantitative 
analysis of the extent of colocalization was performed using 
Zeiss KS300 3.0 Image Processing system. The mean ± 
standard error (SE) percent of colocalization was calculated, 
analyzing a minimum of 50 cells for each treatment randomly 
taken from three independent experiments. Percentage of 
Ki67-positive cells was obtained counting for each treatment 
a total of 500 cells, randomly observed in 10 microscopic 
fields from three different experiments. Results have been 
expressed as mean values ± standard errors (SE). p-values 
were calculated using Student t-test, and significance level 
has been defined as p < 0.05.
Western blot analysis
Melanoma cells were lysed with RIPA buffer; 
50 μg of total protein were resolved under reducing 
conditions by 8% SDS-PAGE and transferred to reinforced 
nitrocellulose (BA-S 83, Schleider and Schuell, Keene, 
NH, USA). The membranes were blocked with 5% 
non fat dry milk in PBS 0.1% Tween 20, and incubated 
with the different primary antibodies. The membranes 
were rehydrated and probed again with anti-GAPDH, to 
estimate the protein equal loading. Densitometric analysis 
was performed using Quantity One Program (Bio-Rad 
Laboratories GmbH) and results were expressed as mean 
values from three independent experiments.
Phospho-RTK array
A human phospho-RTK array (R&D Systems) 
was used to detect simultaneously the phosphorylation 
status of RTKs (n = 49) in melanoma cells. Membranes 
were incubated with cell lysates (100 μg) overnight 
according to the manufacturer’s protocol. After washing, 
the membranes were incubated with a phosphotyrosine 
antibody conjugated to horseradish peroxidase to allow 
the detection of captured RTKs that are phosphorylated. 
Duplicate dots in each corner are positive controls.
RNA extraction and real-time PCR analysis
RNA was extracted using TRIzol method (Invitrogen) 
according to manufacturer’s instruction and eluted with 
0, 1% diethylpyrocarbonate (DEPC)- treated water. Total 
RNA was quantitated by spectrophotometry. Real Time-
PCR was assayed by TaqManW Gene Expression Assays 
(Applied Biosystems, Foster City, CA). To normalize the 
amount of source RNA, 18S transcript from the same 
sample was measured and used as internal reference. Each 
targeted transcript was validated using the comparative 
Ct method for relative quantification (ΔΔCt) reference to 
the amount of a common reference gene (18S). The fold 
difference was calculated using the comparative ΔΔCt 
and results were reported as mean values from three 
independent experiments.
In vitro colony formation assay
Cells viability was determined by crystal violet 
staining. Briefly, the cells were stained for 20 min at room 
temperature with staining solution (0, 5% crystal violet 
in 30% methanol), washed four times with water and 
then dried. Cells were then dissolved in a Methanol/SDS 
solution and the adsorbance (595 nm) was read using a 
microplate ELISA reader.
Statistical analysis
Quantitative analyses for curve fitting and for 
IC50 evaluation were performed by KaleidaGraph and 
by GraphPad softwares. The evaluation of Combination 
Index (CI) was performed by CalcuSyn software using 
the median effect methods described by T-C Chou and P. 
Talalay [53]. Briefly, two molecules are synergic if the CI 
< 1, additive if CI = 1 and antagonist if CI > 1. p-values 
were calculated using Student’s t test and significance 
level has been defined as p < 0.05.
Annexin V binding assay
Annexin V binding assay was performed to quantify 
apoptosis in cells treated with vemurafenib, trametinib, A3 
and A4 alone or in combination. Briefly, 1 × 106 cells were 
treated for 24 hrs with A3 and/or A4 at 20 μg/ ml and drugs 
at variable concentration. After the incubation period, cells 
were washed in PBS and stained with 5 μl of Annexin 
V-FITC (Invitrogen) and PI at 5 μg/ ml (Invitrogen) for 
15 minutes at room temperature in the dark. Apoptosis 
were determined using MACSquant cytofluorometer. Both 
early (Annexin V-positive, PI negative) and late (Annexin 
V-positive, PI positive) apoptotic cells were included in 
cell death determination.
Cell cycle analysis
Cell cycle analysis was performed in cells treated 
or not with A3, A4 alone or in combination at 20 μg/ml 
and/or vemurafenib/trametinib at variable concentration. 
The cell cycle kit, purchased from Millipore, was used 
according to the manufactures’ instructions.
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In vivo efficacy studies
All studies have been performed in accordance with 
the “Directive 2010/63/UE” on the protection of animals 
used for scientific purposes, made effective in Italy by the 
Legislative Decree 4 March 2014, n.26, and applying the 
principles of 3Rs, i.e. replace, reduce, refine. Mice were 
purchased at Harlan Laboratories (Udine, Italy). After 1 
week of acclimatization they were housed five to a plastic 
cage and fed on basal diet (4RF24, Mucedola S.r.l.) with 
water ad libitum, in an animal facility controlled at a 
temperature of 23 ± 2°C, 60 ± 5% humidity, and with a 
12 h light and dark cycle. All procedures performed on 
the animals were approved by Animal Welfare Body and 
authorized by the Italian Ministery of Health, 46/2014-PR. 
At the end of the treatment period and before necropsy, 
mice were euthanized by compressed CO2 gas in cylinder 
as indicated in the AVMA (American Veterinary Medical 
Association) Panel on Euthanasia and according to the 
guidelines described in (UKCCR, 1998.). M14 melanoma 
cells were subcutaneously injected in immunodeficient 
mice at 1 × 106 cells/mouse. Cell were resuspended in 
a 50% RGF matrigel (BD Biosciences) solution in PBS 
and injected in the right flank of the mice in 100 μl 
volume. Treatments started when tumors reached a 100 
mm3 volume and mice were allocated six per group. Mice 
were treated with vehicle (1%Tween80/1%beta-HPCD), 
vemurafenib at 25 mg/kg, trametinib at 0, 5 mg/kg, A3 
and A4 in PBS at 20 mg/kg, or combination of the four. 
Vemurafenib and trametinib were dosed p.o., daily, 5 days/
week, while A3 and A4 antibodies were dosed i.p., once 
per week and treatment lasted for 4 weeks. At the end of 
the treatment mice were euthanized and, after harvesting, 
tumor weight was determined and tumor masses used for 
further analysis.
Histology and immunohistochemistry
Tumor samples from mice were frozen and 
then formalin fixed and paraffin embedded (FFPE). 
Haematoxylin and eosin slides were used to 
evaluate the percentage of tumor necrosis. 
Immunohistochemistry for Ki-67 (clone MIB-1, 
Dako, Denmark) was carried out using the Dako 
automated immunostainer (DAKO, Denmark). Tumor 
proliferation index was assessed as the percentage of 
Ki-67-positive tumor nuclei.
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